Aiforia partners with Stratipath to integrate breast cancer AI tool into Aiforia Clinical Platform

PUBT · 2d ago
Aiforia partners with Stratipath to integrate breast cancer AI tool into Aiforia Clinical Platform
  • Aiforia signed a strategic partnership with Stratipath to broaden access to AI-based diagnostic and prognostic tools in oncology.
  • Deal integrates Stratipath Breast into the Aiforia Clinical Platform, giving labs a single workflow for both companies’ breast cancer applications.
  • Parties plan joint go-to-market efforts to drive adoption of AI precision diagnostics across cancer care centers globally.
  • Stratipath Breast provides AI-based prognostic risk profiling for breast cancer, aligned for clinical use in the EU and UK.
  • Aiforia Breast Cancer Suite is CE-IVD marked in Europe and the EEA, supporting digital breast cancer diagnostics and biomarker assessment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aiforia Technologies Oyj published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.